COMPANY INFO
Insilico Medicine is a private biotechnology company founded in 2014 by Alex Zhavoronkov. It has approximately 350 employees and is headquartered in Boston, Massachusetts, with additional facilities in Hong Kong and New York. The company operates in the drug discovery industry, leveraging artificial intelligence, deep learning, and big data analysis to develop novel drugs and therapeutic solutions targeting cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions. Insilico Medicine's AI-driven platform accelerates drug discovery by combining genomics and machine learning to reduce the time and cost of bringing new medications to market. Its official website is insilico.com.
Insilico Medicine is a biotechnology company founded in 2014 by Alex Zhavoronkov. With headquarters in Cambridge, MA, and major operations in Hong Kong, New York, and other global hubs, Insilico Medicine employs over 350 people. The company specializes in AI-driven drug discovery, using deep learning and big data to accelerate the development of novel therapeutics targeting cancer, fibrosis, immunity, CNS diseases, and age-related conditions. By integrating genomics with advanced machine learning, Insilico Medicine aims to reduce both the cost and time required for new drug development.
Insilico Medicine funding has propelled rapid growth and innovation in the biotech sector. Since its founding, the company has raised a total of $510 million over 12 funding rounds, including grants, seed, and multiple venture rounds. Major milestones include scaling their AI drug discovery platform, expanding into new markets, and advancing a diverse drug pipeline toward clinical validation. The company’s funding strategy has attracted some of the most prominent venture capital firms and strategic investors in the life sciences and technology spaces.
The most recent Insilico Medicine funding round was a Series E, raising $110 million. The funding, led by Value Partners and Pudong Venture Capital, is being used to scale the company's flagship AI-driven drug discovery efforts, expand automated laboratories, and bring clinical-stage drug candidates closer to validation.
This additional Series D funding, led by Prosperity7 Ventures, supported strategic growth initiatives, further expansion of Insilico’s drug pipeline, and development of new AI capabilities.
This Series D round, involving investors like Qiming Venture Partners, BHR, and Warburg Pincus, funded business expansion, technology advancement, and the launch of automated labs. The capital was also allocated to AI platform development and extending applications into areas like green energy and sustainable chemistry.
Insilico Medicine closed its Series C round at $255 million, led by Warburg Pincus and supported by major investors such as Qiming Venture Partners, Eight Roads Ventures, and Sequoia Capital. The funds fueled major scaling, international market expansion, and accelerated product development.
This round, led by Qiming Venture Partners and Eight Roads Ventures, supported further market expansion, the build-up of a senior management team, and development of Insilico’s generative chemistry and AI target identification technologies.
Led by WuXi AppTec and other venture partners, this funding round helped expand Insilico's operations and market presence.
Additional Series A capital was used to accelerate company growth and scale research operations.
Early Series A funding focused on product development and bringing Insilico's platform to market.
Convertible note funding backed early company growth initiatives.
Seed funding, led by Deep Knowledge Ventures, supported the initial launch of Insilico Medicine.
Innovation grants fueled initial R&D efforts.
Additional grant funding supported core research and development.
Value Partners was the lead investor in Insilico Medicine’s Series E round and has been instrumental in advancing the AI-powered drug pipeline and R&D automation.
As a co-lead for the Series E round, Pudong Venture Capital has supported Insilico Medicine in scaling its AI platform and driving clinical innovation.
A prominent investment firm with a focus on growth-stage companies, Warburg Pincus led Insilico Medicine’s Series C and participated in Series D, helping the company scale its operations globally.
Qiming Venture Partners played a significant role across multiple Insilico Medicine funding rounds, including leading Series B and participating in Series C and D, contributing deep expertise in life sciences investments.
The lead in Insilico’s later Series D round, Prosperity7 Ventures supported the company’s strategic global expansion and technological advancement.
Eight Roads Ventures has been a critical investor from Series B through Series C, backing Insilico’s AI capabilities and global growth.
Participating in several rounds, Bold Capital Partners has contributed to Insilico Medicine’s expansion and commercialization efforts.
Pavilion Capital Partners invested in both Series B and C, supporting operational and market expansion.
These investors, across various rounds, provided significant capital and strategic resources, shaping Insilico Medicine’s journey from early-stage innovation to late-stage clinical development. Their participation underscores strong confidence in Insilico Medicine investment opportunities and the future of AI-driven drug discovery.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Insilico Medicine funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.